HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration

Rosenau, Jens; Kreutz, Therese; Kujawa, Matthias; Bahr, Matthias J.; Rifai, K.; Hooman, Nazanin; Finger, Andrea; Michel, Gerd; Nashan, Björn; Kuse, E. R.; Klempnauer, Jürgen; Tillmann, Hans L.; Manns, Michael P.

doi:10.1016/j.jhep.2006.11.022

Cited by 28 publications

(16 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No other HBV polymerase inhibitors were applied in this cohort. Details of the protocols used at Hannover Medical School in the 1990s and early 2000s have been described previously [18,33].…”

Section: Prevention Of Reinfection During and After Liver Transplantamentioning

confidence: 99%

“…The additional loss of anti-HBs caused by binding of anti-HBs to HBsAg particles and HDV virions (HDV RNA) reflects the reduced half-life of virions due to an increase of HBIG in the first days after LTX [18,40] and is modeled with a constant rate k e2 proportional to V D and H:…”

Section: Mathematical Modeling Of Viral Dynamicsmentioning

confidence: 99%

“…This might be explained by low HBV viremias in most HDV-coinfected patients at the time of liver transplantation [17]. Subsequently, very efficient protocols have been established to prevent HBV reinfection, which usually include administration of hepatitis B Immunoglobulin (HBIG) in combination with HBV polymerase inhibitors [18,19]. Applying these standards, long-term survival rates for patients transplanted for HBV cirrhosis are nowadays much better as compared to other causes of end-stage liver disease such as chronic hepatitis C [20].…”

Section: Introductionmentioning

confidence: 99%

“…Up to now there are only few studies on the kinetics of HBV or HCV after liver transplantation [18,[30][31][32]. No study has yet investigated early kinetics of both HDV RNA and HBsAg during the first days and weeks after liver transplantation.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation

Mederacke

Filmann

Yurdaydın

et al. 2012

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

Section: Prevention Of Reinfection During and After Liver Transplantamentioning

confidence: 99%

Section: Mathematical Modeling Of Viral Dynamicsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation

Mederacke

Filmann

Yurdaydın

et al. 2012

Journal of Hepatology

Self Cite

View full text Add to dashboard Cite

“…Immune complexes of HBsAg and anti-HBs antibodies do always occur in chronic hepatitis B and may of course determine HBsAg levels during the time of seroconversion [24]. Thus, antiHBs antibodies have a direct influence on HBsAg levels measured as Rosenau et al [25] have recently shown in the setting of passive immunization during the first days after liver transplantation.…”

Section: Discussionmentioning

confidence: 99%

Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon α plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient

Potthoff

Deterding

Rifai

et al. 2007

European Journal of Gastroenterology & Hepatology

Self Cite

View full text Add to dashboard Cite

Hepatitis B virus (HBV) and hepatitis C virus (HCV) coinfection is frequently associated with progressive liver disease. Treatment options are limited and no data on the efficacy of pegylated interferon (PEG-IFN) plus ribavirin therapy are available. We report a case of a 49-year-old woman with chronic hepatitis B and C who was scheduled for a 48 weeks course of PEG-IFNalpha-2b plus ribavirin therapy. She had HCV genotype 2 infection and was negative for HBV-DNA and HBe antigen before treatment. Although the HCV-RNA response was rapid until week 12, hepatitis B surface antigen (HBsAg) levels showed a more linear decline. At week 48, HBsAg was still positive, however, with very low levels of only 0.06 IU/ml. Treatment was therefore continued for another 4 weeks combined with active HBV immunization until HBs seroconversion occurred. Forty-three weeks after treatment, the patient showed a robust HBs seroconversion (anti-HBs of 260 IU/ml) and a sustained HCV-RNA response. This case highlights that combination therapy of PEG-IFNalpha-2b with ribavirin of HBV/HCV-coinfected individuals cannot only induce a sustained HCV-RNA response but also HBsAg seroconversion in single patients. Monitoring of HBsAg levels can be useful in individualizing optimal treatment duration in HBV-infected patients.

show abstract

What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?

Galli¹,

Orlandini²,

Penzo³

et al. 2008

Journal of Medical Virology

View full text Add to dashboard Cite

To assess quantitative serology in chronic hepatitis B virus (HBV) infection, testing by novel immunoassays has been carried out on 202 specimens from untreated patients and in 83 samples from 10 patients with chronic hepatitis B treated with lamivudine. Serum samples were assayed for quantitative HBsAg, in comparison with quantitative HBV-DNA, and for anti-HBc IgM and the avidity index (AI) of total anti-HBc antibodies. The AI was high (mean: 0.93 +/- 0.19) in all groups, confirming the consistency of this procedure in chronic HBV infections. A low-level positivity (2-28 Paul-Ehrlich units/ml) for IgM anti-HBc was detectable both in HBeAg-positive and in HBeAg-negative untreated chronic hepatitis cases (mean S/CO values by the Abbott Architect assay: 0.51 +/- 0.12 and 0.48 +/- 0.10, respectively; correlation between assays: r = 0.685), while treated patients (mean: 0.20 +/- 0.15) and inactive carriers (mean: 0.17 +/- 0.21), were generally negative for IgM. The levels of HBsAg (IU/ml) showed a weak correlation with HBV-DNA (IU/ml). A difference in HBsAg levels was found between inactive carriers (1,935 +/- 2,887 IU/ml) and chronic hepatitis B cases, either treated (5,199 +/- 9,259 IU/ml) or untreated (14,596 +/- 15,227 IU/ml). Pre-treatment levels of HBsAg in patients undergoing lamivudine treatment were correlated with a sustained response to therapy over 13-33 months (mean: 27.3) of follow-up: mean HBsAg values were 1,576 + 1,487 IU/ml in five responders and 6,063 + 5,142 in five nonresponders or breakthrough responders (P < 0.05). The availability of standardized quantitative immunoassays for HBsAg and anti-HBc IgM may be considered in addition to quantitative HBV-DNA in the staging and monitoring of chronic HBV infection.

show abstract

HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration

Cited by 28 publications

References 45 publications

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation

Rapid early HDV RNA decline in the peripheral blood but prolonged intrahepatic hepatitis delta antigen persistence after liver transplantation

Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon α plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient

What is the role of serology for the study of chronic hepatitis B virus infection in the age of molecular biology?

Contact Info

Product

Resources

About